Relmada_Therapeutics appoints Michael_Quirk

Relmada Therapeutics>>> announced the appointment of Michael Quirk>>>, PhD, as Senior Advisor for its sepranolone program. Michael Quirk>>> brings over 20 years of experience in neuroscience drug discovery and development, including his tenure as Chief Scientific Officer at Sage Therapeutics>>> and a Director at AstraZeneca>>>. His expertise in CNS translational science and neuroactive steroid biology is expected to be instrumental in advancing sepranolone, a GABAA receptor modulator targeting disorders like Prader-Willi Syndrome, Tourette syndrome, and obsessive-compulsive disorder. Michael Quirk>>> holds degrees from Massachusetts Institute of Technology and completed post-doctoral training at Cold Spring Harbor Laboratory. This strategic hire aims to accelerate the clinical development of sepranolone, which has shown an excellent safety profile in over 335 patients to date.